俞旻皓

社會(huì)任職

上海市抗癌協(xié)會(huì)胃腸腫瘤腹腔鏡專(zhuān)業(yè)委員會(huì)委員
中國(guó)醫(yī)療保健國(guó)際交流促進(jìn)會(huì)腔鏡內(nèi)鏡外科分會(huì)委員
上海市抗癌協(xié)會(huì)大腸癌專(zhuān)業(yè)委員會(huì)腸癌轉(zhuǎn)移學(xué)組委員
中國(guó)醫(yī)師協(xié)會(huì)肛腸醫(yī)師分會(huì)腸外腸內(nèi)營(yíng)養(yǎng)專(zhuān)業(yè)學(xué)組委員
中國(guó)醫(yī)學(xué)裝備協(xié)會(huì)腔鏡與微創(chuàng)技術(shù)分會(huì)委員（第一屆）
中國(guó)研究型醫(yī)院學(xué)會(huì)腸外腸內(nèi)營(yíng)養(yǎng)學(xué)專(zhuān)業(yè)委員會(huì)青年委員
《腫瘤醫(yī)學(xué)》專(zhuān)刊第二屆編委會(huì)青年編委會(huì)青年編委
中國(guó)NOSES聯(lián)盟上海分會(huì)理事

獲獎(jiǎng)榮譽(yù)

2011年
仁濟(jì)醫(yī)院優(yōu)秀住院醫(yī)師
2017年
仁濟(jì)醫(yī)院優(yōu)秀單篇圖文微信獎(jiǎng)
2018年
雅培醫(yī)學(xué)營(yíng)養(yǎng)精英挑戰(zhàn)賽-全國(guó)冠軍
揚(yáng)帆遠(yuǎn)航-消化腫瘤精英論壇-十二強(qiáng)優(yōu)勝團(tuán)隊(duì)
2019年
上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院健康科普大賽三等獎(jiǎng)
上海交通大學(xué)醫(yī)學(xué)院“優(yōu)秀青年人才培育計(jì)劃”培訓(xùn)班優(yōu)秀學(xué)員
中國(guó)IBD青年說(shuō)-亞軍（最佳風(fēng)采獎(jiǎng)）
全國(guó)結(jié)直腸腫瘤中青年醫(yī)師-達(dá)醫(yī)生演講大賽-亞軍
結(jié)直腸外科精英團(tuán)隊(duì)臨床技能邀請(qǐng)賽優(yōu)秀獎(jiǎng)
CSCO-賽諾菲消化腫瘤精英論壇-全國(guó)揚(yáng)帆聲勢(shì)比賽十二強(qiáng)
達(dá)醫(yī)生-例達(dá)巔峰-全國(guó)演講大賽總決賽胃腸專(zhuān)場(chǎng)-希望之星
大中華結(jié)直腸腔鏡外科學(xué)院-達(dá)人賽江蘇&上海賽區(qū)-二等獎(jiǎng)
2020年
第十三屆中國(guó)醫(yī)師協(xié)會(huì)外科醫(yī)師年會(huì)“規(guī)范典型病例”
第七屆“上海市健康傳播設(shè)計(jì)大賽——新媒體類(lèi)”三等獎(jiǎng)
上海交通大學(xué)醫(yī)學(xué)院2020年醫(yī)學(xué)專(zhuān)業(yè)課程思政設(shè)計(jì)競(jìng)賽-十佳思政素材
2021年
上海交通大學(xué)醫(yī)學(xué)院醫(yī)學(xué)生健康科普搖籃計(jì)劃科普導(dǎo)師
上海交通大學(xué)醫(yī)學(xué)院健康科普大賽二等獎(jiǎng)-指導(dǎo)老師
上海交通大學(xué)醫(yī)學(xué)院本科優(yōu)秀臨床綜述獎(jiǎng)-指導(dǎo)老師
上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院教學(xué)先進(jìn)個(gè)人

科研成果

發(fā)表論文：
1.第一作者
1)俞旻皓#,王正實(shí),鐘鳴.腹腔鏡修補(bǔ)術(shù)在醫(yī)源性結(jié)腸鏡腸穿孔治療中的應(yīng)用體會(huì)(附7例報(bào)告)[J].腹腔鏡外科雜志,2013,18(11):854-856.
2)俞旻皓#,彭友多,卞正乾,等. 潰瘍性結(jié)腸炎36例手術(shù)治療分析[J]. 中國(guó)臨床醫(yī)學(xué), 2014(6) : 659-660.
3)俞旻皓#,鐘鳴,葉光耀,等. 反穿刺技術(shù)在完全腹腔鏡結(jié)直腸切除術(shù)中的應(yīng)用[J]. 腹腔鏡外科雜志,2014,19(7):497-500.
4)俞旻皓#,王正實(shí),秦紹嵐,等. 腹腔鏡監(jiān)控腸鏡下(LMCP)息肉摘除術(shù)對(duì)比常規(guī)腸鏡下息肉切除的隨機(jī)對(duì)照臨床研究[J]. 現(xiàn)代生物醫(yī)學(xué)進(jìn)展,2015,15(10):1858-1861.
5)俞旻皓#,祁洋,秦紹嵐,等. 腹腔鏡與開(kāi)腹右半結(jié)腸癌全結(jié)腸系膜切除術(shù)的回顧性臨床對(duì)照研究[J]. 外科理論與實(shí)踐,2018,23(2):145-149.
6)郝秀秀#,俞旻皓*,鐘鳴. 早期手術(shù)干預(yù)在小腸克羅恩病治療中的價(jià)值[J]. 胃腸病學(xué),2020,25(4):246-249.
7)俞旻皓#,WANG Q X;ZHANG R;XIAO W W.觀察&等待策略與手術(shù)切除治療新輔助放化療后達(dá)到臨床完全緩解的直腸癌患者療效比較[J].結(jié)直腸肛門(mén)外科,2021,27(2):160-160.
8)Yu M#, Zhong M, Qiao Z*. Expression and clinical significance of cyclin kinase subunit 2 in colorectal cancer. Oncol Lett. 2013 Sep;6(3):777-780. (IF= 2.964)
9)Yu MH#, Luo Y#, Qin SL, Zhong M*. Increased expression of Rab5A predicts metastasis and poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol. 2015 Jun 1;8(6):6974-80.
10)Yu MH#, Luo Y#, Qin SL, Wang ZS, Mu YF, Zhong M*. Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer. Am J Cancer Res. 2015 Aug 15;5(9):2708-18. (IF= 6.164)
11)Yu MH#, Zhang W*. TEAD1 enhances proliferation via activating SP1 in colorectal cancer. Biomed Pharmacother. 2016 Oct;83:496-501. (IF= 6.522)
12)Yu M#, Mu Y#, Qi Y#, Qin S, Qiu Y, Cui R, Zhong M*. Odontogenic ameloblast-associated protein (ODAM) inhibits human colorectal cancer growth by promoting PTEN elevation and inactivating PI3K/AKT signaling. Biomed Pharmacother. 2016 Dec;84:601-607. (IF= 6.523)
13)Yu M#, Luo Y#, Cong Z#, Mu Y, Qiu Y, Zhong M*. MicroRNA-590-5p Inhibits Intestinal Inflammation by Targeting YAP. J Crohns Colitis. 2018 Jul 30;12(8):993-1004. (IF=9.072)
14)Cui R#, Yu MH#, Chen JJ, Qin J, Yue B, Luo Y, Huang YZ, Zhou H, Zhong M*. Monopolar Electrosurgical Scissors Versus Harmonic Scalpel in Robotic Anterior Resection of Rectal Cancer: A Retrospective Cohort Study. J Laparoendosc Adv Surg Tech A. 2019 Jul;29(7):880-885. (IF= 1.874)
15)Yu M#, Cui R#, Huang Y#, Luo Y, Qin S, Zhong M*. Increased proton-sensing receptor GPR4 signalling promotes colorectal cancer progression by activating the hippo pathway. EBioMedicine. 2019 Oct;48:264-276. (IF= 8.142)
16)Luo Y#, Yu MH#, Yan YR#, Zhou Y, Qin SL, Huang YZ, Qin J, Zhong M*. Rab27A promotes cellular apoptosis and ROS production by regulating the miRNA-124-3p/STAT3/RelA signalling pathway in ulcerative colitis. J Cell Mol Med. 2020 Oct;24(19):11330-11342. (IF= 5.313)
17)Cui H#*, Yu W#, Yu M#, Luo Y, Yang M, Cong R, Chu X, Gao G*, Zhong M*. GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression. Cancer Sci. 2021 May;112(5):1798-1810. (IF= 6.710)
18)Luo Y#, Yu MH#, Huang YZ, Jing R, Qin J, Qin SL, Shah JN*, Zhong M*. Lymphadenectomy Around Inferior Mesenteric Artery in Low-Tie vs High-Tie Laparoscopic Anterior Resection: Short- and Long-Term Outcome of a Cohort of 614 Rectal Cancers. Cancer Manag Res. 2021 May 14;13:3963-3971. (IF=3.982)
2.通訊作者
1)Luo Y#, Ye GY#, Qin SL, Mu YF, Zhang L, Qi Y, Qiu YE, Yu MH*, Zhong M*. High expression of Rab3D predicts poor prognosis and associates with tumor progression in colorectal cancer. Int J Biochem Cell Biol. 2016 Jun;75:53-62. (IF= 5.080)
2)Wang ZS#, Zhong M#, Bian YH, Mu YF, Qin SL, Yu MH*, Qin J*. MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer. Oncotarget. 2016 Jul 12;7(28):44266-44276. (IF=4.141)
3)Luo Y#, Qiu YE#, Mu YF, Qin SL, Qi Y, Zhong M, Yu MH*, Ma LY*. Plastic wound protectors decreased surgical site infections following laparoscopic-assisted colectomy for colorectal cancer: A retrospective cohort study. Medicine (Baltimore). 2017 Sep;96(37):e7752. (IF= 1.882)
4)Cong Z#, Ye G#, Bian Z, Yu M*, Zhong M*. Jagged-1 attenuates LPS-induced apoptosis and ROS in rat intestinal epithelial cells. Int J Clin Exp Pathol. 2018 Aug 1;11(8):3994-4003.
5)Luo Y#, Chen JJ#, Lv Q#, Qin J, Huang YZ, Yu MH*, Zhong M*. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway. Cancer Lett. 2019 Jan;440-441:11-22. (IF= 8.674)
6)Cui R#, Yang L#, Wang Y#, Zhong M, Yu M*, Chen B*. Elevated Expression of ASXL2 is Associated with Poor Prognosis in Colorectal Cancer by Enhancing Tumorigenesis and Inducing Cell Proliferation. Cancer Manag Res. 2020 Oct 19;12:10221-10228. (IF= 3.981)
7)Hao X#, Feng T, Yang Y, Shi Y, Jing R, Liu S, Luo Y, Qiao Y*, Zhong M*, Yu M*. Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial. BMJ Open. 2020 Nov 16;10(11):e038429. (IF= 2.692)
8)Shi Y#, He W#, Zhong M*, Yu M*. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases. Genomics. 2021 Jul;113(4):1988-1998. (IF= 5.731)
9)劉澤宇#,鐘鳴,俞旻皓*. 腹腔鏡鏡頭防霧防范的研究進(jìn)展. 外科理論與實(shí)踐[J].2021,26(5):463-465.
10)Zhang L, Yang L, Jiang S, Yu M. Nerve Dependence in Colorectal Cancer. Front Cell Dev Biol. 2022 Feb 10;10:766653.?
11)Liu S, Li L, Sun H, Chen B, Yu M*, Zhong M*. D3 Versus D2 Lymphadenectomy in Right Hemicolectomy: A Systematic Review and Meta-analysis. Surg Innov. 2022 Feb 1:15533506211060230.
3.參與發(fā)表的論文
1)葉光耀#,俞旻皓,鐘鳴*. CKS2在結(jié)直腸癌中的表達(dá)和臨床意義[J]. 胃腸病學(xué),2013,18(3):159-162.
2)卞正乾#,鐘鳴,俞旻皓,等. 經(jīng)肛門(mén)內(nèi)鏡微創(chuàng)手術(shù)治療直腸腫瘤（附74例報(bào)告）[J]. 外科理論與實(shí)踐,2015(2):151-155.
3)駱洋#,卞正乾,葉光耀,俞旻皓,王正實(shí),秦紹嵐,慕逸飛,鐘鳴*. 溶酶體相關(guān)4次跨膜蛋白B對(duì)結(jié)直腸癌增殖和侵襲的影響[J]. 中華胃腸外科雜志,2015(6):606-610.
4)駱洋#,秦紹嵐,俞旻皓,等. 多磷酸肌醇-5-磷酸酶Ⅱ通過(guò)影響 Akt 表達(dá)調(diào)控結(jié)直腸癌增殖和侵襲[J]. 中華消化雜志,2016(1):49-52.
5)慕逸飛#,駱洋,卞正乾,俞旻皓,秦紹嵐,鐘鳴*. ECT2基因在結(jié)腸直腸癌組織中的表達(dá)及意義[J]. 外科理論與實(shí)踐,2016,21(5):395-399.
6)秦紹嵐#,俞旻皓,慕逸飛,等. 全結(jié)腸系膜切除術(shù)在右半結(jié)腸癌根治術(shù)中應(yīng)用的療效[J]. 中華胃腸外科雜志,2016,19(10):1101-1106.
7)秦紹嵐#,俞旻皓,慕逸飛,祁洋,仇伊爾,駱洋,崔然,鐘鳴*.全結(jié)腸系膜切除術(shù)在右半結(jié)腸癌根治術(shù)中應(yīng)用的療效[J].中華胃腸外科雜志,2016,19(10):1101-1106.
8)崔然#,周鴻,俞旻皓,等. 達(dá)芬奇機(jī)器人與腹腔鏡輔助直腸癌前切除的臨床療效對(duì)照研究[J]. 外科理論與實(shí)踐,2017,22(6):499-503.
9)駱洋#,秦駿,陳建軍,俞旻皓,秦紹嵐,仇伊爾,鐘鳴*. 腹腔鏡直腸癌手術(shù)中保留左結(jié)腸動(dòng)脈與否療效對(duì)比研究[J]. 中國(guó)實(shí)用外科雜志,2017,37(6):660-664.
10)駱洋#,陳建軍,秦駿,俞旻皓,秦紹嵐,仇伊爾,鐘鳴*. 腹腔鏡直腸癌根治術(shù)中腸系膜下動(dòng)脈低位結(jié)扎對(duì)第3站淋巴結(jié)清掃的影響及第3站淋巴結(jié)轉(zhuǎn)移危險(xiǎn)因素分析[J]. 中華消化外科雜志,2018,17(2):154-160.
11)駱洋#,俞旻皓,陳建軍,等. 腹腔鏡與開(kāi)腹全結(jié)直腸切除回腸儲(chǔ)袋肛管吻合術(shù)治療潰瘍性結(jié)腸炎的臨床療效分析[J]. 中華消化外科雜志,2018,17(9):929-934.
12)駱洋,俞旻皓,陳建軍,等. 腹腔鏡直腸癌手術(shù)中應(yīng)用中間聯(lián)合頭側(cè)入路療效分析[J]. 中國(guó)實(shí)用外科雜志,2018,38(9):1064-1067,1080.
13)仇伊爾#,駱洋,秦紹嵐,崔然,秦駿,陳建軍,俞旻皓,鐘鳴#. 圍手術(shù)期厚樸排氣合劑在腹腔鏡結(jié)直腸癌快速康復(fù)中療效的隨機(jī)對(duì)照研究[J]. 胃腸病學(xué),2018,23(3):148-151.
14)崔然#,俞旻皓,鐘鳴*. 肛瘺的超聲與MRI檢查以及3D打印模型[J].外科理論與實(shí)踐,2018,23(2):178-180.
15)崔然#,俞旻皓,陳建軍,等. 克羅恩病合并肛瘺的手術(shù)治療進(jìn)展[J]. 胃腸病學(xué),2018,23(4):238-240.
16)顧磊#,劉曄,蔣春暉,俞旻皓,秦駿,徐慶*. 經(jīng)肛全直腸系膜切除術(shù)結(jié)構(gòu)化培訓(xùn)后學(xué)員學(xué)習(xí)效果的評(píng)價(jià)分析[J]. 中華結(jié)直腸疾病電子雜志,2019,8(6):631-635.
17)崔然#,俞旻皓,陳建軍,等. 超聲刀與單極電剪在達(dá)芬奇機(jī)器人輔助直腸癌前切除術(shù)中的療效對(duì)照研究[J]. 中華普通外科雜志,2019,34(1):66-67.
18)李靖#,李軍,呂強(qiáng),王海川,鐘鳴,駱洋,秦駿,俞旻皓,蔡曉燕*. 結(jié)直腸癌腫瘤組織中IncRNA-MVIH和micRNA的表達(dá)及早期診斷意義[J].中國(guó)腫瘤臨床與康復(fù),2019(5):521-524.
19)秦駿#,史苑,敬然,俞旻皓,陳建軍,張斌,顧磊,蔣春暉,葉光耀,孫隆慈,Shah Jay N,鐘鳴*. 外科醫(yī)師非手術(shù)臨床技能評(píng)分標(biāo)準(zhǔn)中導(dǎo)師評(píng)價(jià)的研究[J]. 中華醫(yī)學(xué)教育探索雜,2019,18(10):1043-1047.
20)駱洋#,俞旻皓,陳建軍,等. 臍上縱行輔助切口在腹腔鏡直腸癌手術(shù)中應(yīng)用的優(yōu)勢(shì)探討[J]. 中華胃腸外科雜志,2020,23(3):289-293.
21)李靖#,陳建軍,應(yīng)雋,姜建平,駱洋,俞旻皓,鐘鳴*. 加速康復(fù)外科在腹腔鏡結(jié)直腸癌手術(shù)中的應(yīng)用及對(duì)免疫功能的影響[J]. 腹腔鏡外科雜志,2020,25(11):853-858.
22)劉賽靚#,周勇,俞旻皓,等. 右半結(jié)腸癌淋巴結(jié)清掃范圍的臨床研究進(jìn)展[J]. 中華結(jié)直腸疾病電子雜志,2020,9(5):507-511.
23)敬然#,駱洋,秦駿,康紅梅,黃軼洲,俞旻皓,鐘鳴*. 吻合口支架降低結(jié)腸術(shù)后吻合口漏發(fā)生率的動(dòng)物研究[J]. 中華結(jié)直腸疾病電子雜志,2020,9(6):581-585.
24)駱洋#,俞旻皓,樊釗強(qiáng),等. 腹腔鏡低位直腸癌術(shù)中預(yù)防性轉(zhuǎn)流術(shù)的選擇標(biāo)準(zhǔn)——仁濟(jì)經(jīng)驗(yàn)[J]. 腹腔鏡外科雜志,2020,25(11):801-803.
25)駱洋#,俞旻皓,陳建軍,等. 倒刺縫線在腹腔鏡直腸癌根治術(shù)中加固吻合口的應(yīng)用價(jià)值[J]. 中華消化外科雜志,2020,19(11):1205-1210.
26)鐘鳴#*,駱洋,俞旻皓. 保留左結(jié)腸動(dòng)脈腹腔鏡直腸癌根治術(shù)的解剖基礎(chǔ)與外科實(shí)踐[J]. 中華外科雜志,2020,58(8):600-603.
27)貢婷月#,俞旻皓,鐘鳴*. 初始可切除結(jié)直腸癌肝轉(zhuǎn)移新輔助治療研究進(jìn)展[J]. 中華胃腸外科雜志,2021,24(3):279-282.
28)駱洋#,俞旻皓,樊釗強(qiáng),等. 結(jié)直腸外科專(zhuān)業(yè)化程度對(duì)腹腔鏡低位直腸癌術(shù)預(yù)防性造口的影響[J]. 腹腔鏡外科雜志,2021,26(2):112-116.
29)史苑#,俞旻皓,鐘鳴*. 英夫利西單克隆抗體治療炎癥性腸病的療效預(yù)測(cè)標(biāo)志物研究進(jìn)展[J]. 中華炎性腸病雜志,2021,05(2):169-173.
30)孫凌宇#,俞旻皓,駱洋,HUANG Y Z.腸系膜下動(dòng)脈根部淋巴結(jié)清掃聯(lián)合血管低位或高位結(jié)扎治療直腸癌的效果觀察[J].結(jié)直腸肛門(mén)外科,2021,27(04):392-393.
31)Cong ZJ#, Hu LH#, Bian ZQ#, Ye GY, Yu MH, Gao YH, Li ZS, Yu ED*, Zhong M*. Systematic review of anastomotic leakage rate according to an international grading system following anterior resection for rectal cancer. PLoS One. 2013 Sep 25;8(9):e75519.
32)Luo Y#, Qin SL#, Yu MH, Mu YF, Wang ZS, Zhong M*. Prognostic value of regulator of G-protein signaling 6 in colorectal cancer. Biomed Pharmacother. 2015 Dec;76:147-52.
33)Luo Y#, Ye GY, Qin SL, Yu MH, Mu YF, Zhong M*. ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells. Gastroenterol Res Pract. 2015;2015:936564.
34)Zhang Y#, Luo Y#, Qin SL, Mu YF, Qi Y, Yu MH, Zhong M*. The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology. 2016 Mar 10;5(5):e1141857.
35)Zhou Y#, Qiu YE#, Qin SL, Luo Y, Cui R, Qin J, Chen JJ, Yu MH, Zhong M, Shi XY*. Expression of CHD5 may serve as an independent biomarker of prognosis in colorectal cancer via immunohistochemical staining. Int J Clin Exp Pathol. 2018 May 1;11(5):2792-2798.
36)Chen J#, Luo Y#, Zhou Y#, Qin S, Qiu Y, Cui R, Yu M, Qin J, Zhong M*. Promotion of Tumor Growth by ADAMTS4 in Colorectal Cancer: Focused on Macrophages. Cell Physiol Biochem. 2018;46(4):1693-1703.
37)Qiu YE#, Qin J#, Luo Y, Qin SL, Mu YF, Cun R, Jiang HL, Chen JJ, Yu MH, Zhong M*. Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression. Prostaglandins Other Lipid Mediat. 2018 May;136:9-14.
38)Cao D#, Luo Y, Qin S, Yu M, Mu Y, Ye G, Yang N, Cong Z, Chen J, Qin J, Cui R, Jing R, Cao H, Zhong M*. Metallopanstimulin-1 (MPS-1) mediates the promotion effect of leptin on colorectal cancer through activation of JNK/c-Jun signaling pathway. Cell Death Dis. 2019 Sep 10;10(9):655.
39)Xu W#, Yu M, Qin J, Luo Y, Zhong M*. LACTB Regulates PIK3R3 to Promote Autophagy and Inhibit EMT and Proliferation Through the PI3K/AKT/mTOR Signaling Pathway in Colorectal Cancer. Cancer Manag Res. 2020 Jun 30;12:5181-5200.
40)Lyu L#, Chen D, Yu M, Yang Y#. The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2020 Nov;32(11):1480-1481.
41)Hong HJ#, Zhao X, Yu CR, Sun J, Dong F, Zang L, Lu AG, Feng B, Wang ML, Yu MH, Qiu ZJ, Qian BY, Xie L, Fingerhut A, Zheng MH*, Ma JJ*, Zhong M*. Comparative study of oncologic efficacy of cephalomedial to lateral dissection versus medial to lateral dissection in laparoscopic total mesorectal excision for rectal cancer: An RCT study. J Surg Oncol. 2021 May;123 Suppl 1:S65-S75.
發(fā)表著作：
1、《消化外科臨床解剖與常用手術(shù)技巧》，林擎天、黃建平主編，上海，上海交通大學(xué)出版社，2013，ISBN 978-7-313-10090-0/R，第三篇第二十八章第三節(jié)“腹腔鏡下結(jié)腸穿孔修補(bǔ)術(shù)”，編委
2、《精編結(jié)直腸腫瘤臨床診治》，鐘鳴主編，北京，科學(xué)技術(shù)文獻(xiàn)出版社，2020.11，ISBN 978-7-5189-7340-8，副主編
3、《現(xiàn)代普外疾病診治與微創(chuàng)技術(shù)》，鐘鳴等主編，背景，科學(xué)技術(shù)文獻(xiàn)出版社，2020.12，ISBN 978-7-5189-7465-8，副主編
國(guó)際會(huì)議發(fā)言&壁報(bào)：
1.Speech: International College of Surgeons United States Section, 79th Annual Surgical Update, A Retrospective Controlled Clinical Study of Hand-assisted Laparoscopic and Open Colectomy in Right-side Colon Cancer, 15-17 June 2017, Seattle, Washington USA.
2.Speech: Asia Pacific Colorectal Endoscopic Summit (APCES), Pros and Cons of Left Colic Artery Preserving Technique, 13 January 2018, Shanghai, China.
3.Poster Presentation: World Congress of Gastroenterology, Increased Proton-sensing Receptor GPR4 Promotes Colorectal Cancer Progression by Activated Non-canonical Hippo Pathway, 21-24 September 2019, Istanbul, Turkey.
承擔(dān)課題：
1.國(guó)家自然科學(xué)基金委員會(huì)，青年項(xiàng)目，81702300，轉(zhuǎn)錄因子TEAD1介導(dǎo)YAP1的促結(jié)直腸癌發(fā)展的分子機(jī)制研究，2018.1.1-2020.12.31，20萬(wàn)，已結(jié)題
2.上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院臨床科研培育基金，PYZY16-016，腹腔鏡右半結(jié)腸癌全系膜切除術(shù)的安全性和療效評(píng)價(jià)，2016.1.1-2018.12.31，35萬(wàn)，已結(jié)題
3.上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院臨床科研培育基金，PYIII20-14，腹腔鏡下根治性右半結(jié)腸癌淋巴清掃范圍的隨機(jī)對(duì)照研究，2020.12-2022.11，10萬(wàn)
發(fā)明專(zhuān)利：
實(shí)用新型專(zhuān)利：
1、一種腹腔鏡鏡頭防霧裝置（CN201821346860.0），俞旻皓，鐘鳴，崔然
2、腹腔鏡手術(shù)助手訓(xùn)練裝置（CN201921108447.5），鐘鳴，陳建軍，駱洋，崔然，秦駿，俞旻皓
3、一種用于預(yù)測(cè)大腸癌化療效果的生物標(biāo)志物、試劑盒及其應(yīng)用（CN202010069465.8），洪潔，陳豪燕，張昕雨，馬丹，房靜遠(yuǎn)，俞旻皓
4、一種具有輔助照明裝置的手術(shù)牽開(kāi)器（CN202020168819.X），俞旻皓，崔然，徐一藝，鐘鳴，劉澤宇
雜志編委：
International Journal on Research Case Reports and Case Series
雜志審稿人：
Scientific Reports
Cell Cycle
Journal of International Medical Research
Clinical and Experimental Pharmacology and Physiology
Pathology Research and Practice
OncoTargets and Therapy
Clinical Case Reports Journal
Cancer Biotherapy and Radiopharmaceuticals
Cancer Management and Research
Cancer Biology & Therapy
Molecular Medicine Reports
Acta Biochimica et Biophysica Sinica
《中國(guó)醫(yī)學(xué)前沿雜志》

進(jìn)修經(jīng)歷

工作經(jīng)歷

教育經(jīng)歷